DE60327069D1 - Verbesserte reinigungsmethode für viren - Google Patents

Verbesserte reinigungsmethode für viren

Info

Publication number
DE60327069D1
DE60327069D1 DE60327069T DE60327069T DE60327069D1 DE 60327069 D1 DE60327069 D1 DE 60327069D1 DE 60327069 T DE60327069 T DE 60327069T DE 60327069 T DE60327069 T DE 60327069T DE 60327069 D1 DE60327069 D1 DE 60327069D1
Authority
DE
Germany
Prior art keywords
viruses
cleaning method
improved cleaning
improved
cleaning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327069T
Other languages
English (en)
Inventor
Matthew C Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29406789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60327069(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DE60327069D1 publication Critical patent/DE60327069D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material
DE60327069T 2002-04-30 2003-04-28 Verbesserte reinigungsmethode für viren Expired - Lifetime DE60327069D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37727302P 2002-04-30 2002-04-30
US44317603P 2003-01-29 2003-01-29
PCT/CA2003/000624 WO2003093463A1 (en) 2002-04-30 2003-04-28 Improved viral purification methods

Publications (1)

Publication Number Publication Date
DE60327069D1 true DE60327069D1 (de) 2009-05-20

Family

ID=29406789

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327069T Expired - Lifetime DE60327069D1 (de) 2002-04-30 2003-04-28 Verbesserte reinigungsmethode für viren

Country Status (17)

Country Link
US (3) US7223585B2 (de)
EP (1) EP1501921B2 (de)
JP (1) JP2005523722A (de)
AR (1) AR039783A1 (de)
AT (1) ATE427990T1 (de)
AU (1) AU2003229159B2 (de)
BR (1) BR0309659A (de)
CA (1) CA2482512C (de)
DE (1) DE60327069D1 (de)
DK (1) DK1501921T4 (de)
ES (1) ES2323454T5 (de)
HK (1) HK1070670A1 (de)
IL (1) IL164551A (de)
MX (1) MXPA04010603A (de)
NZ (1) NZ535944A (de)
TW (1) TWI317378B (de)
WO (1) WO2003093463A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501921B2 (de) 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Verbesserte reinigungsmethode für viren
AU2004249802B2 (en) * 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US8373381B2 (en) 2005-04-22 2013-02-12 GM Global Technology Operations LLC DC/DC-less coupling of matched batteries to fuel cells
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
WO2007123961A2 (en) 2006-04-20 2007-11-01 Wyeth Purification processes for isolating purified vesicular stomatitis virus from cell culture
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AU2009296628B2 (en) * 2008-09-24 2015-01-15 Medimmune, Llc Methods for purification of viruses
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
ES2681434T3 (es) * 2013-03-15 2018-09-13 The Children's Hospital Of Philadelphia Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
CN105900240A (zh) * 2014-01-14 2016-08-24 皇家飞利浦有限公司 有机发光二极管
WO2016130569A1 (en) * 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN107207556B (zh) 2014-11-14 2020-12-08 沃雅戈治疗公司 调节性多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP3793615A2 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
MX2021000810A (es) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP4010465A1 (de) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
EP4192514A1 (de) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
JPS6344532A (ja) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk 豚のレオウイルス感染症ワクチン
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CA2189882C (en) 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
ES2278399T3 (es) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
CA2274876A1 (en) 1996-12-13 1998-06-18 Schering Corporation Method for purifying viruses
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
MXPA03007535A (es) 2001-03-16 2003-12-11 Oncolytics Biotech Inc Metodo para extraer virus de cultivo celular.
EP1501921B2 (de) 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Verbesserte reinigungsmethode für viren
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
EP1501921B1 (de) 2009-04-08
DK1501921T4 (da) 2012-10-08
US8685734B2 (en) 2014-04-01
JP2005523722A (ja) 2005-08-11
EP1501921B2 (de) 2012-07-25
HK1070670A1 (en) 2005-06-24
DK1501921T3 (da) 2009-06-22
WO2003093463A1 (en) 2003-11-13
NZ535944A (en) 2007-11-30
US10167452B2 (en) 2019-01-01
TWI317378B (en) 2009-11-21
BR0309659A (pt) 2005-02-22
AR039783A1 (es) 2005-03-02
US7223585B2 (en) 2007-05-29
MXPA04010603A (es) 2004-12-13
US20040005693A1 (en) 2004-01-08
US20140178969A1 (en) 2014-06-26
US20070269856A1 (en) 2007-11-22
CA2482512C (en) 2011-09-20
ES2323454T3 (es) 2009-07-16
CA2482512A1 (en) 2003-11-13
TW200401829A (en) 2004-02-01
ES2323454T5 (es) 2012-11-14
IL164551A (en) 2010-05-17
EP1501921A1 (de) 2005-02-02
ATE427990T1 (de) 2009-04-15
AU2003229159A1 (en) 2003-11-17
AU2003229159B2 (en) 2008-02-21
IL164551A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
DE60327069D1 (de) Verbesserte reinigungsmethode für viren
NO20054134D0 (no) Renseprosess
BRPI0313238A2 (pt) método
DE60309521D1 (de) Distanzhalter für Stäbe
NO20022644L (no) Renseprosess
DE60333287D1 (de) Reinigungsverfahren für alkoxystyrolpolymere
DE60333210D1 (de) Desinfektionsmethode
DE502004008685D1 (de) Fadenführervorrichtung für ringspindel
NO20035626D0 (no) Metode
DE50301369D1 (de) Kuvertierstation für postbearbeitungssysteme
NO20035401D0 (no) Metode
DE602004031650D1 (de) Drehbund für hubsäge
NO20023358D0 (no) Metode
ITMO20030335A1 (it) Apparato per pulizie.
DE60312109D1 (de) Reinigungsvorrichtung für eine Anode
FI20030546A0 (fi) Puhdistuslaite, puhdistustyökalu ja puhdistuslaitteen käyttötapa
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
FR2841888B1 (fr) Plate-forme de nettoyage
DE10297729T8 (de) Gasreinigungssystem
DE502004009748D1 (de) Vorspanneinrichtung für weblitzen
ATE377067T1 (de) Aufbrausendes reinigungsmittel
SE0202650D0 (sv) New method
SE0203388D0 (sv) New method
SE0201576D0 (sv) New method
SE0201024D0 (sv) New method

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: BENEDUM, U., DIPL.-CHEM.UNIV.DR.RER.NAT., PAT.-ANW